No Pharma Love for Schering
551973
A doubling of earnings, but no jump in stock price?
442828
Schering's hepatitis C drug works as well as Roche's.
640534
Its failure to acquiesce to the FDA's request means the competition is going forward as this drugmaker's product stays stagnant.
520589
Investors are discouraged after it releases the latest data for its top drug.
83518
Merck & Co and Schering-Plough Corp said a closely watched study involving its Vytorin cholesterol treatment failed to reach its main goal.
348152
The German drug maker Bayer said its third-quarter profit fell 35 percent on costs related to its acquisition of a rival, Schering, but its performance still exceeded analystsÂ expectations. Bayer earned 320 million euros ($419 million) in the three months through September, down from 493 million euros a year earlier. Sales rose 26 percent, to 7.78 billion euros ($10.2 billion). The company, based in Leverkusen, said it booked special charges totaling 139 million euros ($182 million) in the quarter, with 106 million euros ($139 million) of that mostly attributable to the integration of its health care unit with Schering. Bayer bought Schering in June in a deal worth nearly 16.9 billion euros ($22 billion) to strengthen its health care business. The company said its health care unit was Âthe principal growth engine for BayerÂs business in the third quarter,Â with sales climbing 73 percent, to 3.48 billion euros ($4.56 billion).
285833
An experimental antidiarrhea drug made by Genzyme Corp. failed its first large test in humans, the company said yesterday, the second disappointment for the Cambridge biotechnology giant in two days.
746919
Drug maker Schering-Plough Corp   on Tuesday reported a fourth-quarter loss as special  charges from its acquisition of Organon Biosciences late last  year offset sharply higher sales.
184248
Averse to risk? Check out these nontraditional drug companies.
303738
Drug and medical device makers will not be forced to disclose the results of clinical trials on some products that never reached the marketplace.
457661
U.S. regulators need more clinical trials before they can approve heart-scan contrast agent MS-325 from Germany's Schering and U.S. partner Epix Pharmaceuticals, the companies said on Friday.
725625
German chemicals and pharmaceuticals giant Bayer says it is still open to further acquisitions even though it was still in the process of integrating Berlin-based drug maker Schering which it recently acquired for close to 17 billion euros (22 billion dollars).
710615
Schering ups '04 earnings, Yasmin sales forecasts (4:41 AM ET) LONDON (CBS.MW) -- German drugmaker Schering( SHR )(DE:717200DE:717200)said it was upping its 2004 earnings forecast on a more favorable tax rate ...
370237
Schering-Plough's positive study results send shares of Vertex down.
401679
Genzyme Corp. suffered an unaccustomed defeat yesterday when shareholders in Bioenvision Inc. , a small New York cancer-drug developer, blocked a $350 million takeover bid by refusing to sell their stock to the Cambridge biotechnology giant.
732137
U.S. health officials said on Friday they would review whether to take regulatory action over Merck & Co Inc and Schering-Plough's cholesterol medicine Vytorin following the drug's failure to work better than a generic drug in a study of plaque build-up in neck arteries.
160808
Akzo Nobel  said on Monday it was selling its drugs unit Organon BioSciences to Schering-Plough  for 11 billion euros ($14.5 billion), dropping plans to float it in a public share offer.